Skip to main content
  • Ocellaris Pharma Inc.
  • Investment: 2019
  • Status: Active

Ocellaris Pharma, Inc., Montréal, is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TVM Life Science Innovation II SCSp.

Ocellaris is developing a biologic adressing multiple oncology indications. Target is a member of the tumor necrosis factor (TNF) receptor family and considered highly relevant for new immuno-oncology treatments.

Involved Team

Dr. Luc Marengère
Managing Partner

Caroline Fortier (CEO)